naloxol
Small moleculeexperimental
Naloxol is an opioid antagonist closely related to naloxone. It exists in two isomeric forms, α-naloxol and β-naloxol. — Wikipedia
Clinical trial activity
1 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Mar 1, 2012 (NCT01533155)
Timeline
2010s
- Jan 1, 2012
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Delta opioid receptorANTAGONIST
OPRD1 antagonist
- Kappa opioid receptorANTAGONIST
OPRK1 antagonist
- Mu opioid receptorANTAGONIST
OPRM antagonist
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaNaloxol ↗
Also known as
- naloxol
- naloxol
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01533155 | Phase 1 | Mar 1, 2012 | AstraZeneca, IQVIA |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| AstraZeneca | For profit | 1 | 1 | 1 | 2012 |
| IQVIA | For profit | 1 | 0 | 1 | 2012 |
2 organizations
Page 1 / 1